Back to News
NewsJobsInflationInterest Rates

Moderna Shares Surge Following Cancer Treatment Success

Moderna's stock soared 131% following successful Phase 3 trial results for its personalized mRNA cancer treatment combined with Keytruda.

Mercation Admin
August 19, 2026 2 min read
Moderna Shares Surge Following Cancer Treatment Success

Summary

  • Moderna's stock skyrocketed approximately 131% after the Phase 3 INTerpath-001 trial showed success with its personalized mRNA therapy paired with Keytruda for melanoma treatment.
  • The therapy, known as intismeran autogene, customizes treatment based on tumor mutations, enhancing the immune response alongside Merck's Keytruda.
  • Short sellers faced about $4.8 billion in losses as Moderna's shares more than doubled, with short interest at 13.5% of the free float.

Moderna achieved a major breakthrough with its personalized mRNA cancer vaccine, which successfully completed its first Phase 3 trial, leading to a significant market response.

On Wednesday, Moderna’s shares surged roughly 131%, reaching nearly $148 with an intraday peak of $163, marking a record single-day gain. Merck, which produces Keytruda, also saw its stock rise significantly following the news.

The Phase 3 INTerpath-001 trial demonstrated that the combination of intismeran autogene and Keytruda improved recurrence-free and distant metastasis-free survival rates in patients with stage IIB–IV melanoma post-surgery.

This achievement represents the first positive result for a personalized neoantigen therapy in a Phase 3 trial and the first success for an mRNA-based treatment in oncology.

About the Treatment

Intismeran autogene, also referred to as V940 or mRNA-4157, is not a conventional drug. It is tailored to each patient, with healthcare providers analyzing tumor mutations to create mRNA that prompts the immune system to recognize and combat cancer cells.

Keytruda, an anti-PD-1 agent, boosts immune cell activity. The combination of these treatments has shown to be more effective than Keytruda alone, representing a significant advancement in post-surgical cancer therapy.

For Moderna, this trial outcome is pivotal as the company has faced challenges following a downturn in COVID-related sales and significant short-selling activity. The recent surge in stock price reflects a broader market reaction where investors rush to cover their short positions to limit losses, reminiscent of the GameStop trading scenario in 2021.

Peter Hillerberg, co-founder of ORTEX, noted, "With each shorted share now down almost $100, this kind of pressure is precisely what can lead to a squeeze." The trial will continue to evaluate overall survival rates and other secondary endpoints yet to be disclosed.